CARE Research, LLC Chooses Science Exchange as the Primary Online Channel to Offer Preclinical In Vivo Services to Scientists

March 6, 2018 | Posted by Team in News |

CARE Research on Science Exchange

PALO ALTO, CA, March 6, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development services, announced a partnership with CARE Research, LLC to offer online access to its preclinical services to scientists around the globe.

CARE Research, LLC is a Colorado-based contract research organization (CRO) and a foremost provider of preclinical research. The company’s mission is to deliver services that are competitively priced, of superior quality, and rendered with a high degree of responsiveness that ensures ease of FDA approval.

“Our partnership with Science Exchange allows us to widen our operational reach and to find clients we wouldn’t have connected with had we only used our internal resources,” said Rajan Bawa, Ph.D., co-founder and CEO of CARE Research, LLC. “Additionally, the project managers with whom we have interacted are very responsive, helpful and easily available to answer any questions and facilitate sponsor interactions.”

“We are excited to partner with CARE Research, LLC to make its preclinical in vivo services readily available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is steadfastly committed to adding new innovative and qualified providers to our platform, so scientists have quick access to a breadth of research services. CARE Research, LLC met our rigorous standards for quality and compliance while demonstrating breakthrough discoveries in the field of in vivo research.”

About CARE Research, LLC

CARE Research, LLC is a leader in customized preclinical studies with quick turnaround, competitive costing and humane animal handling procedures under strict regulatory compliance. Our experienced, hands-on scientists design and conduct studies that facilitate regulatory approval. Our studies enable both large and small life science companies to achieve their design and exploration goals as well as obtain marketing approval. Our services include a wide range: PK/ MTD, DART, toxicology, IND/NDA enabling studies for drugs and biomedical devices. Our clinical pathology and histopathology capabilities afford a single point of control to our study sponsors. We offer a variety of animal models including rodents, rabbits, dogs, guinea pigs, pigs, mini pigs, goats, sheep, cattle, and horses.  

Need animal studies? Submit your preclinical study scope of work to receive a quote from the CARE Research team:

Tech Q&A with CARE Research

February 12, 2018 | Posted by Team in Provider Spotlight |


 

Chandreyee Das, PhD, of Science Exchange recently spoke with Rajan Bawa, PhD, of CARE Research LLC, a leading preclinical CRO combining quality service for clients with excellent quality of life for animals — even for challenging or complex projects.

CD: Rajan, you’ve been in the pharmaceutical and biotechnology industry for over 40 years, can you tell us your company’s story?

RB: Twenty years ago, I started this histopathology company, Colorado Histo-Prep. In 2010, we acquired one of our preclinical CRO clients, which was CARE Research, enabling us to provide a one-stop-shop for our clients in the preclinical space.

CD: What capabilities does CARE Research have that set the company apart from other preclinical CROs?

RB: One differentiator is our ability to start projects very swiftly, with quick IACUC approval. We have extensive technical and regulatory experience.

Also, our responsiveness to our sponsor needs, being proactive in providing ongoing progress reports — we don’t wait until things go wrong.

We’re relatively small — we have about 20 people — but that means that we have high-ranking people in our organization — say, VP of Toxicology, or IACUC chairs — actively involved in projects. In large preclinical CROs, very often, there’s a study director who sits in his office, doesn’t even make it to the lab until the sponsor comes to visit.

CD: What preclinical services do you offer that are differentiated from other service providers?

RB: One area of strength is in DART (Developmental and reproductive toxicology) studies and ocular studies. DART services are not often offered by small or medium CROs, because they lack the expertise to carry out these specialized studies.

Ocular studies are another of our core competencies — these are also complex studies, you really have to know what you’re doing.

CD: What type of certifications does CARE Research hold?

RB: That’s a great question. We are OLA certified, AAALAC accredited, and we are GLP. We’re inspected regularly by FDA and USDA.

CD: What types of clients do you serve?

RB: We have a mix of different sponsors. We have large pharma, small biomedical companies, university researchers, startup companies.

In addition to our flexibility and ability to respond quickly, we have the ability to do very complex projects, especially in the surgical and ocular area in contrast to other CROs who may stay away from complex studies.

CD: Finally, could you describe your experience with Science Exchange?

RB: Science Exchange allows us to widen our reach, and allows us to find clients we would not have found using our internal resources. Also, the project managers whom I’ve interacted with are very helpful and responsive, and easily available to answer any questions, provide clarifications, etc in a patient manner.

 

Request a quote from CARE Research and get on the fastest path to completing your preclinical studies.

request quotes button

 

Tech Q&A with Likarda, LLC

February 5, 2018 | Posted by Team in Provider Spotlight |


Guru Singh, Director of Scientific Content, recently spoke with Dr. Lisa Stehno-Bittel, President and Founder of Likarda LLC, an exciting biotech service company on the Science Exchange network.


GS: Nice to meet you, Lisa! Why do clients come to Likarda?

LSB: Likarda is the company you come to when your scientific questions require complex solutions. Our scientists work to create and validate novel assays on a number of different projects, in a timely and efficient manner.

GS: What capabilities does Likarda have that differentiate the company from other service providers and cell-based assay experts?

LSB: We have a strong portfolio of platform technologies that allow us to conduct assays that just aren’t available at other companies. First of all, we have a series of patents around generating, in a high throughput manner, 3D spheroids for drug screening, efficacy testing, toxicity testing, etc. Our Likarda CC Microplate is made using standard plate formats, but in each well of a 384-well plate are 150 different single microwells, in each of which we can grow a different spheroid. That way, we can reduce the number of replicates, saving time and money for the client.

GS: There are many different plate-based models on the market — organoplates, microfluidic chips, etc. — How do Likarda’s plates compare?

LSB: The difference is that Likarda’s plates are really made for a high throughput format and are ideal for complex experiments, for example, when you need to work with multi-cell-type 3D cultures, in an as natural environment as possible. Most of the time, we don’t use any sort of gel or matrix for the 3D cultures — the plates are low-adherence, so the cells stick to each other and not to the plate. This makes the plates easy to work with. We do have a patented hydrogel technology which allows us to make microencapsulated cells using biocompatible materials. We are the first to use these materials for microencapsulation. Microplates and hydrogel — these two technologies really set us apart.

GS: Very cool. How would you describe Likarda’s team?

LSB: All of our scientists have advanced Masters’ degrees in biology or physiology or PhD’s in physiology or bioengineering. We’re a relatively small team, so everyone is involved and gives input into these complex studies that we typically do.

GS: Your clients seem very diverse!

LSB: Yes! Our clients are in the pharmaceutical and nutraceutical industries, as well as food supplements and hygiene. We do work for multinational companies as well as smaller startups.

GS: How has Likarda grown over the years? What lies in the future?

LSB: We started Likarda 5 years ago with money from family and friends. Within 17 months, we were revenue-positive! We’re revenue-driven, and we’re working also on our own products — microplates, hydrogel, regenerative medicine therapies we’re getting ready to take to market.

GS: Can you talk about Likarda’s certifications?

LSB: We’re a woman-owned company, we have the capability to run GLP studies, and we can maintain GMP status for drug development projects, we have continual environmental monitoring.

GS: So, I take it, Likarda has had a successful experience being part of the Science Exchange network.

LSB: Definitely — Science Exchange has been wonderful to work with! With Science Exchange, you have a sourcing agent assigned to you from the very start. That person really does a good job of figuring out what the client needs, and matching them to the right CRO for their research.

Connect with the Likarda team to discuss your project today by visiting www.scienceexchange.com/labs/likarda-llc.

New on Science Exchange: VR Tech, Cancer Genetics, Stem Cell-based Organoids

October 26, 2017 | Posted by Team in Innovation Highlight, New Innovations |

Chandreyee Das, Ph.D. | Senior Content Manager, Science Exchange | www.scienceexchange.com

Nanome Virtual Reality

Virtual Reality Software: Explore biology at nanoscale

From “Fantastic Voyage” (1966) to “A Wind in the Door” (1973), fiction has adored the idea of exploring the body at cellular and molecular levels. Now, virtual reality (VR) software, combined with the computational power afforded by blockchain technology, makes such journeys possible.

For your next computer-aided drug discovery/development (CADD) project, especially if you are collaborating with researchers across multiple sites, try molecular visualization using VR technology — now available from Nanome through Science Exchange.

Visit the Nanome storefront to connect with their team!

 

Cancer Genetics: Connect patients to discoveries

It’s a great day for precision medicine, with the unveiling of the first global directory of patient-derived xenografts (PDX).

Despite the attention given to precision medicine, however, less than 5% of cancer patients are participating in clinical trials. In the discovery phases of R&D, obtaining biospecimens of specific genotypes is also a continuing challenge.

Oncologists on Science Exchange can now accelerate their research with Cancer Genetics, Inc., a global CRO with a history of thought leadership in precision medicine.

Start a project today with Cancer Genetics, Inc.

 

Stem Cell-based 3D Organoids: Predict Preclinical Efficacy and Toxicity

3Dnamics Organoid Hippocampus

Organoids, particularly brain organoids, have enabled breakthrough research in Alzheimer’s disease, glioblastoma, and even ZIKA virus-induced microcephaly. By using pluripotent stem cells as a source of the multiple cell types present in an organoid, preclinical researchers can recapitulate in vivo-like tissue architecture and cellular heterogeneity.

Many of these discoveries were made by the founders of 3Dnamics, a new service provider on the Science Exchange network. The 3Dnamics team was built by stem cell pioneers and neuroscientists at Johns Hopkins University School of Medicine. If you are in the process of developing a model system for your preclinical or discovery-phase research, take advantage of 3Dnamics’ expertise.

Visit the 3Dnamics storefront

 

Small Biotech Stories: Eos Neuroscience

November 26, 2013 | Posted by Brianne Villano in Innovation Highlight |

Eos Neuroscience is a company built on collaboration, featuring a unique team with expertise in transgenes, virology and gene expression, and retinal degeneration. Once they complete their preclinical stage, their intended userbase would be those with blindness attributed to photoreceptor degeneration, or age-related macular degeneration.

They are running into some problems in the process of preclinical research, however. Alan Horsager, Co-Founder and CSO, describes his experience, “As a whole, biotech needs to deeply reevaluate the process, all the way from discovery to market. It’s so arduous that so few impactful drugs make it to market. There are certain gene therapies making it through, but the path is not easy at all. We say ’20 years and $200 million.'”

In light of difficulties and the expense of developing technologies, companies like Alan’s are trying to find ways to do things more efficiently, and their team is so unique that it’s difficult to recreate that collaboration. So rather than trying to clone themselves, they’re on Science Exchange.

“Science Exchange provides the opportunity to bring experts together toward a common goal, a network of distributed team members.” says Alan. “You can’t have an organization that has all the people and equipment that you need. You need expertise in different areas and Science Exchange provides a central location where you can go to get the experts.”

If your business encompasses multiple research areas, it is often difficult to access all the equipment and researchers you need in house. Eos does a wide range of research including vector development, qPCR, and gene expression, but in varying degrees and not constantly. So having the ability to do all that in house when you’re not doing the research full-time doesn’t make much sense.

Alan elaborated, “You can hire a postdoc for $70K per year, and theoretically they do more than a PCR assay, but if they don’t do it right it takes extra time and there’s a lot of training involved. If you’re only doing a couple of different assays, it’s probably better to hire someone and do it internally. But if you’re doing a lot of different assays, it’s better to seek external experts because it’s a fraction of the cost.”

We have actually found that researchers can save up to 46% on various experiments like immunohistochemistry (IHC), cloning, and sequencing, so Alan is absolutely right. Any product that enables you to order services from scientific experts across the world at significant discounts is worth a second look.

About Eos Neuroscience:
Eos has designed and managed clinical programs in gene therapy and the eye and has been involved in all aspects of primary research including transgenes, virology and gene expression, and retinal degeneration. Their worldwide core of experts has expertise covering basic research through clinical/regulatory.

About the author

    Brianne is dedicated to customer support and development for Science Exchange. She     is a formally trained biologist with a M.S. in Biotechnology whose past experience at           Charles River Laboratories sparked a flame for building client relationships.

 

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By WPFruits.com